Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS

被引：0
|
作者：
Tombal, B. [1 ]
Smith, M. R. [2 ]
Hussain, M. [3 ]
Saad, F. [4 ]
Fizazi, K. [5 ]
Sternberg, C. N. [6 ]
Crawford, E. D. [7 ]
Kapur, S. [8 ]
Zhang, W. [9 ]
Ploeger, B. [10 ]
Li, R. [11 ]
Kuss, I. [12 ]
Zieschang, C.
Wittemer-Rump, S.
Rezazadeh, Kalebasty A. [13 ]
机构：
[1] Clin Univ St Luc, Dept Urol, Brussels, Belgium
[2] Massachusetts Gen Hosp Canc Ctr, Dept Oncol, Boston, MA USA
[3] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[4] Univ Montreal, Dept Urol, Hosp Ctr, Montreal, PQ, Canada
[5] Univ Paris Saclay, Inst Gustave Roussy, Villejuif, France
[6] Englander Inst Precis Med, Weill Cornell Dept Med, New York, NY USA
[7] Univ Calif San Diego, Dept Urol, Sch Med, San Diego, CA USA
[8] Bayer SEA, Dept Med Affairs, Singapore, Singapore
[9] Bayer Healthcare Pharmaceut Inc, Clin Pharmacol, Whippany, NJ USA
[10] Bayer AG, Clin Pharmacol, Berlin, Germany
[11] Bayer Healthcare Pharmaceut Inc, Dept Stat, Whippany, NJ USA
[12] Bayer AG, Clin Dev, Berlin, Germany
[13] Univ Calif Irvine, Div HematologyOncol, Orange, CA USA
来源：
EUROPEAN UROLOGY | 2023年 / 83卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A1184
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of darolutamide in combination with androgen-deprivation therapy (ADT) and docetaxel in Black/African-American patients from the phase 3 ARASENS trial
    Shore, Neal D.
    Hussain, Maha H. A.
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Tombal, Bertrand
    Nordquist, Luke
    Cookson, Michael
    Jhaveri, Jay
    Thiele, Silke
    Srinivasan, Shankar
    Ortiz, Jorge
    Smith, Matthew R.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2023, 32 (01) : 218 - 219
  • [22] Efficacy and safety of darolutamide in combination with androgen-deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial
    Tombal, B.
    Hussain, M.
    Saad, F.
    Fizazi, K.
    Shore, N.
    Kopyltsov, E.
    Boegemann, M.
    Mendez-Vidal, M. J.
    Littleton, N.
    Srinivasan, S.
    Verholen, F.
    Smith, M. R.
    EUROPEAN UROLOGY, 2024, 85 : S1585 - S1585
  • [23] Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?
    Hoeh, Benedikt
    Chun, Felix K. H.
    Mandel, Philipp
    CHINESE CLINICAL ONCOLOGY, 2024, 13 (01)
  • [24] Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis
    Tan, Pui San
    Aguiar Jr, Pedro
    Haaland, Benjamin
    Lopes, Gilberto
    PROSTATE CANCER AND PROSTATIC DISEASES, 2018, 21 (04) : 516 - 523
  • [25] Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis
    Pui San Tan
    Pedro Aguiar
    Benjamin Haaland
    Gilberto Lopes
    Prostate Cancer and Prostatic Diseases, 2018, 21 : 516 - 523
  • [26] Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone- sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.
    Aydogdu, Can
    Urban, Florian
    Tamalunas, Alexander
    Berg, Elena
    Tz, Melanie Go Spacing Diaeresis
    Rodler, Severin
    Heinemann, Volker
    Stief, Christian
    Casuscelli, Jozefina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [27] Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Ito, Tetsuro
    Grant, Laura
    Duckham, Bryony R.
    Ribbands, Amanda J.
    Gater, Adam
    ADVANCES IN THERAPY, 2018, 35 (12) : 2186 - 2200
  • [28] Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Tetsuro Ito
    Laura Grant
    Bryony R. Duckham
    Amanda J. Ribbands
    Adam Gater
    Advances in Therapy, 2018, 35 : 2186 - 2200
  • [29] Additional cycles of docetaxel in combination with androgen deprivation therapy (D-ADT) in metastatic hormone- sensitive prostate cancer (mHSPC): Efficacy and feasibility analysis.
    Aydogdu, Can
    Urban, Florian
    Tamalunas, Alexander
    Berg, Elena
    Goetz, Melanie
    Rodler, Severin
    Unterrainer, Lena
    Heinemann, Volker
    Stief, Christian G.
    Casuscelli, Jozefina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).
    Barata, Pedro C.
    Emamekhoo, Hamid
    Mendiratta, Prateek
    Gopalakrishnan, Dharmesh
    Koshkin, Vadim S.
    Tyler, Allison Janine
    Ornstein, Moshe Chaim
    Grivas, Petros
    Gilligan, Timothy D.
    Rini, Brian I.
    Kyriakopoulos, Christos
    Garcia, Jorge A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
12345